These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8676708)

  • 21. Immunologic therapy for secondary and primary progressive multiple sclerosis.
    Myers LW
    Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
    Kampman MT; Steffensen LH
    Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
    [No Abstract]   [Full Text] [Related]  

  • 23. New treatments for multiple sclerosis.
    McDonald WI
    BMJ; 1995 Feb; 310(6976):345-6. PubMed ID: 7866205
    [No Abstract]   [Full Text] [Related]  

  • 24. A 29-year-old man with multiple sclerosis.
    Rudick RA
    JAMA; 1998 Oct; 280(16):1432-9. PubMed ID: 9801004
    [No Abstract]   [Full Text] [Related]  

  • 25. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
    Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
    Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
    [No Abstract]   [Full Text] [Related]  

  • 26. [Diagnostics and drug therapy of multiple sclerosis].
    Suomen Neurologinen Yhdistys ry
    Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
    [No Abstract]   [Full Text] [Related]  

  • 27. Update on MS treatment.
    Ryan M
    J Am Pharm Assoc (Wash); 1996 Jul; NS36(7):419-20. PubMed ID: 8840740
    [No Abstract]   [Full Text] [Related]  

  • 28. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J; Freedman M
    Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
    [No Abstract]   [Full Text] [Related]  

  • 29. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory treatment of MS in Slovenia.
    Sega-Jazbec S
    Clin Neurol Neurosurg; 2002 Jul; 104(3):249-50. PubMed ID: 12127663
    [No Abstract]   [Full Text] [Related]  

  • 31. Interferon beta and glatiramer acetate therapy.
    McGraw CA; Lublin FD
    Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.
    Cadavid D; Cheriyan J; Skurnick J; Lincoln JA; Wolansky LJ; Cook SD
    J Neurol Neurosurg Psychiatry; 2009 Dec; 80(12):1337-43. PubMed ID: 19687024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New therapeutic agents in the management of multiple sclerosis].
    Besson G; Carpentier F
    Presse Med; 1998 Dec; 27(39):2032-5. PubMed ID: 9893694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of multiple sclerosis with interferon beta-1 b.
    Abdul-Ahad A; Shah S; Galazka A
    Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.